Clinical trials: Advanced Breast Cancer Stage IV
Breast Cancer Metastatic, Breast Cancer Brain Metastases
Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis
In phase Ib, our study is aimed to evaluate the safety and tolerance of SHR-A1811 combined with pyrotinib in breast cancer with brain metastasis, and confirm the recommended phase 2 dose combined with preliminary results of…
- Trial name
- NCT06718933
- Testing
- SHR-A1811, Bevacizumab, Pyrotinib
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Fudan University
Breast Cancer Metastatic, Advanced Breast Cancer
Decision Support Tool for Patients With Advanced Breast Cancer
The goal of this pilot study is to understand and improve the shared decision-making process between people with advanced breast cancer and their providers regarding their care and treatment.
- Conditions
- Breast Cancer Metastatic, Advanced Breast Cancer, Stage 4 Breast Cancer, Stage IV (Metastatic) Breast Cancer
- Trial name
- COAST (NCT07635147)
- Testing
- Decision Support Tool
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Weill Medical College of Cornell University
Metastatic Breast Cancer
Study of the Efficacy and Safety of Letrozole Combined With Trastuzumab in Patients With Metastatic Breast Cancer
Phase IV trial to investigate the effect of the combination of Letrozole with trastuzumab in metastatic breast cancer patients
- Trial name
- eLEcTRA (NCT00171847)
- Testing
- Letrozole, Trastuzumab plus Letrozole
- Where
- Germany
- Volunteers
- 93 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Gastric Cancer
A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC)
This multicenter study will assess the maximum tolerated dose (MTD) of capecitabine in combination with Kadcyla (trastuzumab emtansine) in participants with HER2-positive mBC or HER2-positive LA/mGC using a Phase 1 design…
- Trial name
- TRAXHER2 (NCT01702558)
- Testing
- Capecitabine, Trastuzumab emtansine (T-DM1)
- Where
- 40 sites in Argentina, Brazil and 10 more
- Volunteers
- 182 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer Metastatic
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study
The purpose of this study is to find out the possible anti-cancer effect of pelareorep in combination with chemotherapy [paclitaxel] and avelumab in treating a type of breast cancer called Hormone Receptor positive (HR+)/Human…
- Trial name
- NCT04215146
- Testing
- Paclitaxel, Pelareorep, Avelumab
- Where
- 18 sites in United States
- Volunteers
- 48 people
- Sponsor
- Oncolytics Biotech
Breast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer
Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)
This study tests the safety and preliminary anti-tumor activity of an investigational dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy in adults with advanced breast cancer.
- Conditions
- Breast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer, Triple-Negative Breast Cancer (TNBC)
- Trial name
- DUAL-NK-BC (NCT07486089)
- Testing
- Dual-target CAR-NK cells (EB-DT-CAR-NK), Lymphodepleting chemotherapy, Supportive care
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Biotech
Breast Cancer
Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France
This study is a national, multicenter, prospective, non-interventional study in women with HR+/HER2- locally advanced or metastatic breast cancer (BC), for which a prior clinical decision to initiate ribociclib + endocrine…
- Trial name
- RosaLEE (NCT05697146)
- Testing
- ribociclib + ET
- Where
- 82 sites in France
- Volunteers
- 1,019 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Metastatic Breast Cancer
AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer
The purpose of this study is to assess safety and tolerability of AZD2014 when given in combination with Fulvestrant
- Trial name
- NCT01597388
- Testing
- AZD2014, Fulvestrant
- Where
- 5 sites in United States
- Volunteers
- 99 people
- Sponsor
- AstraZeneca
Breast Cancer, Invasive Breast Cancer
Onvansertib + Paclitaxel In TNBC
This research is being done to evaluate the safety and effectiveness of Onvansertib in combination with Paclitaxel in triple-negative breast cancer (TNBC) that has spread to other parts of the body.
- Conditions
- Breast Cancer, Invasive Breast Cancer, Unresectable Breast Carcinoma, Locally Advanced Breast Cancer
- Trial name
- NCT05383196
- Testing
- Onvansertib, Paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Antonio Giordano, MD
Breast Tumors
Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis
Multicenter, open-label phase II trial assessing the efficacy of DS-8201a monotherapy in patients with metastatic breast cancer.
- Trial name
- DAISY (NCT04132960)
- Testing
- DS-8201a
- Where
- 15 sites in France
- Volunteers
- 186 people
- Sponsor
- UNICANCER
Metastatic Breast Cancer
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
This study was a multicenter, randomized, double-blind, placebo-controlled Phase III study to determine the efficacy and safety of treatment with Buparlisib plus Fulvestrant vs.
- Trial name
- BELLE-3 (NCT01633060)
- Testing
- Fulvestrant, BKM120
- Where
- 197 sites in United States, Argentina and 20 more
- Volunteers
- 432 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called ARV-471) when given together with other medicines for the potential treatment of advanced or metastatic breast cancer.
- Trial name
- NCT05573555
- Testing
- ARV-471, Ribociclib
- Where
- 31 sites in United States, Canada and 2 more
- Volunteers
- 20 people
- Sponsor
- Pfizer
Neoplasms, Breast Neoplasms
Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer
The main purpose of this study is to compare progression free survival in patients treated with AZD8931 given in combination with anastrozole versus anastrozole alone.
- Conditions
- Neoplasms, Breast Neoplasms, Breast Cancer
- Trial name
- MINT (NCT01151215)
- Testing
- AZD8931, anastrozole
- Where
- 60 sites in United States, Brazil and 16 more
- Volunteers
- 482 people
- Sponsor
- AstraZeneca
Breast Cancer
Herceptin Followed by Chemotherapy in Treating Women With Metastatic Breast Cancer That Overexpresses HER2
RATIONALE: To compare efficacy, toxicity and quality of life of the sequential administration of Her alone followed, at PD, by the combination with Chemotherapy (Arm A) vs.
- Trial name
- NCT00004935
- Testing
- Herceptin™ (Her), Herceptin™ (Her) + chemo
- Where
- 17 sites in Italy, Switzerland
- Volunteers
- 175 people
- Sponsor
- Swiss Cancer Institute
Breast Cancer
Monoclonal Antibody Therapy in Treating Women With Locally Advanced or Metastatic Breast Cancer Previously Treated With Combination Chemotherapy
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00066547
- Testing
- monoclonal antibody HuHMFG1
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Estrogen-receptor-positive Breast Cancer, Metastatic Breast Cancer
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
The goal of this research study is to compare a combination of two drugs, capecitabine and elacestrant to capecitabine alone as a treatment for advanced estrogen receptor-positive (ER+) breast cancer.
- Conditions
- Estrogen-receptor-positive Breast Cancer, Metastatic Breast Cancer, Breast Cancer, Hormone Receptor Positive Breast Cancer
- Trial name
- CAPELA (NCT07222215)
- Testing
- Capecitabine, Elacestrant
- Where
- United States
- Volunteers
- 297 people
- Sponsor
- Kristina A. Fanucci
Advanced Breast Cancer, Metastatic Breast Cancer
A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.
The study is being conducted to assess the efficacy and safety of SHR6390 combined with famitinib in the treatment of advanced or metastatic breast cancer that progress in 1-2 line endocrine therapy.
- Trial name
- NCT04733417
- Testing
- SHR6390, famitinib
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Breast Cancer
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
A study to assess the efficacy and safety of Dato-DXd in the pre-chemotherapy setting for patients with metastatic HR-positive, HER2 IHC 0 breast cancer.
- Trial name
- TB06 (NCT07205822)
- Testing
- Dato-DXd
- Where
- 40 sites in United States, China and 4 more
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Breast Neoplasms, BRCA 1 Gene Mutation
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)
The purpose of this open-label, 2:1 randomized phase III trial is to compare the safety and efficacy of talazoparib (also known as BMN 673) versus protocol-specific physician's choice in patients who have locally advanced and/or…
- Conditions
- Breast Neoplasms, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation
- Trial name
- EMBRACA (NCT01945775)
- Testing
- talazoparib, Physician's-Choice
- Where
- 362 sites in United States, Australia and 14 more
- Volunteers
- 431 people
- Sponsor
- Pfizer
Breast Cancer
Abiraterone Acetate in Molecular Apocrine Breast Cancer
The purpose of this study is to estimate antitumour activity of abiraterone acetate in Patients with a Molecular Apocrine HER2-negative locally advanced or metastatic Breast Cancer.
- Trial name
- AMA (NCT01842321)
- Testing
- Abiraterone Acetate
- Where
- 36 sites in France
- Volunteers
- 34 people
- Sponsor
- UNICANCER
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.